- Home
- HURA vs PROV Comparison
HURA vs PROV Comparison
Compare HURA & PROV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- PROV
- Stock Information
- Founded
- HURA 2009
- PROV 1956
- Country
- HURA United States
- PROV United States
- Employees
- HURA N/A
- PROV N/A
- Industry
- HURA
- PROV Savings Institutions
- Sector
- HURA
- PROV Finance
- Exchange
- HURA Nasdaq
- PROV Nasdaq
- Market Cap
- HURA 103.3M
- PROV 100.7M
- IPO Year
- HURA N/A
- PROV 1996
- Fundamental
- Price
- HURA $2.64
- PROV $15.50
- Analyst Decision
- HURA Strong Buy
- PROV Hold
- Analyst Count
- HURA 2
- PROV 1
- Target Price
- HURA $11.50
- PROV $16.50
- AVG Volume (30 Days)
- HURA 500.9K
- PROV 7.3K
- Earning Date
- HURA 08-15-2025
- PROV 07-28-2025
- Dividend Yield
- HURA N/A
- PROV 3.61%
- EPS Growth
- HURA N/A
- PROV N/A
- EPS
- HURA N/A
- PROV 0.97
- Revenue
- HURA N/A
- PROV $39,909,000.00
- Revenue This Year
- HURA N/A
- PROV $3.06
- Revenue Next Year
- HURA $69.15
- PROV $9.15
- P/E Ratio
- HURA N/A
- PROV $15.97
- Revenue Growth
- HURA N/A
- PROV 1.24
- 52 Week Low
- HURA $1.80
- PROV $12.41
- 52 Week High
- HURA $9.94
- PROV $16.70
- Technical
- Relative Strength Index (RSI)
- HURA N/A
- PROV 49.37
- Support Level
- HURA N/A
- PROV $15.25
- Resistance Level
- HURA N/A
- PROV $15.90
- Average True Range (ATR)
- HURA 0.00
- PROV 0.35
- MACD
- HURA 0.00
- PROV -0.03
- Stochastic Oscillator
- HURA 0.00
- PROV 42.03
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About PROV Provident Financial Holdings Inc.
Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. Through the bank, it is engaged in providing community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. The company's business segment is Bank. The Bank's activities include attracting deposits, offering banking services, and originating and purchasing single-family, multi-family, commercial real estate, construction, and other mortgage loans and, to a lesser extent, commercial business and consumer loans held for investment.